Crystallization and polymorphic transitions of chlorpropamide in aqueous 2-hydroxybutyl-β-cyclodextrin solution

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 4, 2010, Pages 248-255

  Ishiguro, Takako ^a,b   Hirayama, Fumitoshi ^a   Iohara, Daisuke ^a   Arima, Hidetoshi ^b   Uekama, Kaneto ^a  

^a SOJO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

2 Hydroxybutyl cyclodextrin; Chlorpropamide; Crystallization; Polymorph; Solution mediated polymorphic transition

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHLORPROPAMIDE;

AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPERATURE DEPENDENCE; X RAY DIFFRACTION;

BETA-CYCLODEXTRINS; BUTANOLS; CHLORPROPAMIDE; CRYSTALLIZATION; PHARMACEUTICAL SOLUTIONS; SOLUBILITY; WATER;

EID: 75149115652     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.12.008     Document Type: Article

References (24)

1. Al-Saieq S.S., and Riley G.S. Polymorphism in sulphonylurea hypoglycaemic agents. II. Chlorpropamide. Pharm. Acta Helv. 57 (1982) 8-11
2. Bernstein J. Polymorphism in Molecular Crystals (2002), Oxford University Press, Oxford
3. Bernstein J. Polymorphism in Molecular Crystals (2002), Oxford University Press, Oxford 66-93
4. In: Brittain H.G. (Ed). Polymorphism of Pharmaceutical Solids (2009), Marcel Dekker, New York
5. Burger A. Zur polymorphie oraler antidiabetika, 1: chlorpropamid. Sci. Pharm. 43 (1975) 152-161
6. Byrn S.R. Solid-state Chemistry of Drugs (1982), Academic Press, New York
7. De Villiers M.M., and Wurster D.E. Isothermal interconversion of chlorpropamide polymorphs kinetically quantified by X-ray powder diffractometry, diffuse reflectance Fourier transform infrared spectroscopy and isoperibol solution calorimetry. Acta Pharm. 49 (1999) 79-88
8. Drebushchak V.A., Drebushchak T.N., Chukanov N.V., and Boldyreva E.V. Transition among five polymorphs of chlorpropamide near the melting point. J. Therm. Anal. Calorim. 93 (2008) 343-351
9. Higuchi T., and Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4 (1965) 117-212
10. Iohara D., Hirayama F., Ishiguro T., Arima H., and Uekama K. Preparation of amorphous indomethacin from aqueous 2,6-di-O-methyl-β-cyclodextrin solution. Int. J. Pharm. 354 (2008) 70-76
11. Ishiguro T., Hirayama F., Iohara D., and Uekama K. Prominent inhibitory effect of 2-hydroxybutyl-β-cyclodextrin on solution-mediated polymorphic transition of chlorpropamide. Chem. Lett. (2008) 816-817
12. Job P. Formation and stability of inorganic complexes in solution. Ann. Chem. 9 (1928) 113-203
13. Loftsson T., and Brewster M.E. Pharmaceutical applications of cyclodextrin. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85 (1996) 1017-1025
14. Macie C.M.G., and Grant D.J.W. Crystal growth in pharmaceutical formulation. Pharm. Int. 7 (1986) 233-237
15. Nogami H., Nagai T., and Yotsuyanagi T. Dissolution phenomena of organic medicinals involving simultaneous phase changes. Chem. Pharm. Bull. 17 (1969) 499-509
16. Ostwald W. Studien uber die Bildung und Umwandlung Fester Korper. Z. Physik. Chem. 22 (1897) 289-302
17. Rajewski R.A., and Stella V.J. Pharmaceutical applications of cyclodextrin. 2. In vivo drug delivery. J. Pharm. Sci. 85 (1996) 1042-1069
18. Rodriguez-Hornedo N., and Murphy D.J. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J. Pharm. Sci. 88 (1999) 651-660
19. Simmons D.L., Ranz R.J., and Gyanchandani N.D. Polymorphism in pharmaceuticals. III. Chlorpropamide. Can. J. Pharm. Sci. 8 (1973) 125-127
20. Sonoda Y., Hirayama F., Arima H., Yamaguchi Y., Saenger W., and Uekama K. Cyclodextrin-based isolation of Ostwald's metastable polymorphs occurring during crystallization. Chem. Commun. (2006) 517-519
21. Sonoda Y., Hirayama F., Arima H., Yamaguchi Y., Saenger W., and Uekama K. Selective crystallization of metastable form IV polymorph of tolbutamide in the presence of 2,6-di-O-methyl-β-cyclodextrin in aqueous solution. Cryst. Growth Des. 6 (2006) 1181-1185
22. Ueda H., Nambu N., and Nagai T. Dissolution behavior of chlorpropamide polymorphs. Chem. Pharm. Bull. 32 (1984) 244-250
23. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. 52 (2004) 900-915
24. Vemavarapu, C., Mollan, M.J., Needham, T.E., 2002. Crystal doping aided by rapid expansion of supercritical solutions. AAPS PharmSciTech, 3 article 29. URL: http://www.aapspharmsci.org.